Overblog Seguir este blog
Edit post Administration Create my blog
3 octubre 2010 7 03 /10 /octubre /2010 17:41

 PRESS RELEASE ON MEXICO'S

2ND ANNUAL POST POLIO SYNDROME SYMPOSIUM

  Liliana Marasco Garrido, President and Co-Founder of Litaff

and  

         Shari Fiksdal, President & Co-Founder of International

                   Post Polio Support 

THE LATEST NEWS ON POST POLIO SYNDROME (PPS)

Three important issues came from the symposium, we feel it is important that we share this latest news with everyone.

Some may already know there is a WHO Code for Post Polio Syndrome, that there is

a possible marker waiting for approval by the ...Journal 

 And that they are continuing to find IV Gamma globulin is helping those

of us with PPS!  We apologize that this release has been delayed due to to ill health.

LATEST INVESTIGATIONS INTO THE CAUSE OF POST  POLIO SYNDROME 

                         image003.jpg

 

DSCF0260

Dr. Brian Joseph, PhD. (Harvard) brought us up to date on IV Gamma Globulin Studies of

Dr. H. Gonzalez! Dr. Kristian Borg and Henrick Gonzalez in Sweden have been working for

many years testing the benefits of IV Gamma Globulin for PPS patients. 

Dr. Joseph asked Dr. Henrik Gonzalez about their test results since their last release in 2008. 

Dr. Joseph explained that the tests being done in Sweden by

Dr. Henrick Gonzalez and Dr.  Kristian Borg had proven to be successful

and their research into the cause of PPS was “revolutionary


1.   The study proved gamma helps PPS.

2.  The study shows we have fragments of polio protein in our spinal cords, which causes our immune systems to continue to battle the polio virus that was there.  This and not dying neurons is what is causing PPS by weakening our immune systems.  Our body is still in the fight mode to kill off the tiny polio fragments in our bodies.  This does not mean we still have polio,  just remnants of the old virus our immune systems are still attacking, causing further degeneration.

 3.  And even more importantly, they have found a blood test to tell if you have PPS!                                                                                                                                  

Dr. Brian Joseph 

The details will all be released as soon as the peer review process is complete.

Here is a letter from Dr. Henrik Gonzalez to Liliana Marasco Garrido of Litaff confirming the statements above!

From: Henrik Gonzalez

Date: 5 de agosto de 2010 14:34:29 CDT

 To: "Asociacion Postpolio Litaff A.C_ APPLAC" <litaffac@prodigy.net.mx>

 RE: Re: Dr. Henrik Gonzales Regards From México PPS Organization

 Very nice to hear from You Liliana.

 Brian and I have corresponded for some years.  For your information, we have two unpublished studies.

 

When studies are unpublished I am not able to tell you too much about the results, but:

 The first is the one year follow up of Xepol (IVIG) with very promising results and the other

 a method to diagnose PPS by a very simple blood test.

  Very warm regards

 Henrik

 You can read below that Grifols has already bought the rights to Xepol:                             

http://www.grifols.com/web/noticias2.aspseccion=5&subseccion=1&tercero=0&idNoticia=224&valor=Post%20Polio

 

Mtra. RitaVelásquez Lerma,

Subdirectora de Registros de Salud y Discapacidad Del INEGI


Sin título1ppp-copia-1

 

World Health Code  for  PPS “G 14” for PPS:          

 

In 2009 and as a result of the annual meeting of the Committee on

Review and Update of the World Health Organization (WHO), which

took place in the Indian capital Delhi during the month of October 2008,

the International Classification Diseases, version 10 (ICD-10) has been awarded

specific location to Post-Polio Syndrome (PPS) classified under

the code "G14" and excluded from code B91 (Sequelae of poliomyelitis), which

considered it before this body covered. International Statistical Classification of

Diseases and Related Health Problems. "With these changes the codes are assigned by

the WHO as one can read:"

 

 

Classification of polio sequelae and late effects and secondary

(ICD-10, WHO) .                                 

 http://www.cihi.ca/cihiweb/en/downloads/ICD-10-A_Vol1_2009.pdf

                                                         G14 Postpolio 

                  Includes:  Post Polio  Syndrome   -  Excludes: Postpolio Sequelae

  Dr. Susanna Reyes Rodriguez presented the latest information on

 

 

 

 

Transfer Factor and IV Gamma studies in Mexico!

                                                 trasfer

DSCF0247

 

Dra. Rodriguez is already using Transfer Factor in Mexico and had just finished

her studies with PPS and IV gamma. 

Dra. Rodriguez said she had found gamma to be helpful in other

Central Nervous System illnesses

and was looking forward to furthering her studies with PPS. 

 She had one medical institution and  Dr. Carlos Vallbona  volunteer to help her work with these studies.

                                                      Warm regards to all,

       Sin títuloliliana            shai      

   Mrs.  Liliana Marasco Garrido                             Shari Fiksdal, President & Co-Founder  

    Post Polio Association Litaff ,A.C_APPLAC                                         International Post Polio Support Org. 

          Sin título19                                                                               Sin título18

     

                                                     ernesto

                                                        Mr. Ernesto Maury Ruiz

                                                    Vice President & Cofounder

  

Websites:  APPLAC http://www.postpoliolitaff.org  or http://www.mexicopostpolio.com

                        IPPSO http://www.ippso-world.org 

Email       APPLAC litaffac@prodigy.net.mx  

                        IPPSO Fiksdalpps@yahoo.com

                 Tel/Fax  : Litaff (52) 55742926     IPPSO  (01) 541-772-1102

 © ® To republishedthis this press release you must get permission from

Liliana  Marasco Garrido or Shari Fiksdal and it must be republished in

it's entirety if permission is received.

Prohibida su publicación, todos los derechos reservados, solicitar

permiso a Liliana Marasco Garrido Presidenta y Fundadora de

APPLAC o a Mrs Shari Fiksdal ©®


      STOCKHOLM, SWEDEN – 26 August, 2008 ‐

 Pharmalink AB today announces positive results from a follow‐on Phase III study of Xepol®,

its candidate for the treatment of post‐polio syndrome (PPS). The data have shown the candidate to be effective an
d well tolerated with no serious adverse events attributed to the product being reported in the treated patients.
The Phase III study, involving 142 patients, is a placebo controlled, double blind trial designed to evaluate the efficacy
and safety of Xepol® in PPS, a neurological pain and weakness syndrome in patients that have survived poliovirus infection.
The original placebo controlled, double blind Phase III trial was six months
(Gonzalez et al (2006) Lancet Neurology 5:493‐500)
and this follow‐ up period was another six months.
The follow‐on results strengthen the position of this novel treatment modality for PPS by demonstrating a reduction of
inflammatory  cytokines in the cerebrospinal fluid and a significant reduction of symptoms of PPS while also showing that Xepol®
is safe and well tolerated with few or no side‐effects. Endpoints studied were pain, walking ability and SF‐36 scores (a common self assessment scoring system that measures physical and psychological variables).
 All showed significant and clinically meaning fulresults. Full results are to be published in a peer review journal.
 Xepol®, the first medical PPS treatment , is an injectable biologic product, administered once per 9‐12 months, which down
‐regulates the inflammatory process in the nervous system of PPS patients. The concept and medical hypothesis was first developed by Dr Henrik Gonzalez and Professor Kristian Borg, scientists at the Karolinska Institute (Sweden)
. Pharmalink licensed the invention and is now working to bring the candidate towards registration.

 

“We are very encouraged by the outcome of the follow‐up analysis as it is clear from the results that Xepol brings relief from pain and muscle weakness to PPS patients,” said Johan Häggblad, Managing Director of Pharmalink.
“We are very excited about this data as currently there is no medical treatment for PPS and patients in the treated group have experienced a reduction in disease symptoms after just 12 months.”

 

“It is very rewarding to see that Xepol is demonstrating efficacy and the potential to help PPS patients,” said inventor and principal investigator Professor Kristian Borg. “We are looking forward to expanding the Xepol treatment procedure following product registration.”

 

Pharmalink is actively seeking a partner to bring Xepol® to the market. More than 1000 PPS patients have been treated with the drug and many return on an annual basis for new treatment courses. Xepol® has already achieved Orphan Drug Designation in the US and is patented in the major markets.

cytokines
 citocinas 2

 

 


 

Compartir este post

Repost 0
APPLAC APPLAC - en Post Polio

Applac

  • APPLAC
  • Siendo que tenemos muy presente como Organización Civil nuestra dirección en representar a las personas que padecen de secuela de polio y a sus familias, a los que ya padecen del Síndrome de Post Polio (SPP)
  • Siendo que tenemos muy presente como Organización Civil nuestra dirección en representar a las personas que padecen de secuela de polio y a sus familias, a los que ya padecen del Síndrome de Post Polio (SPP)

Páginas